Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 3, 2014, Pages 561-569

  Han, Jae A ^a   Kang, Young Ji ^a   Shin, Changsik ^a   Ra, Jae Sun ^a   Shin, Hyun Hee ^a   Hong, Sung You ^a   Do, Yoonkyung ^a   Kang, Sebyung ^a  

^a Ulsan National Institute of Science and Technology   (South Korea)

Author keywords

Antigen delivery; Dendritic cells; Ferritin; Protein cage; Vaccine

Indexed keywords

ANTIGENS; CELL PROLIFERATION; CELLS; CYTOLOGY; NANOPARTICLES; PEPTIDES; VACCINES;

ANTIGEN DELIVERY; ANTIGENIC PEPTIDES; DENDRITIC CELLS; EXTERIOR SURFACES; FERRITIN; FERRITIN PROTEIN; PROTEIN CAGES; VACCINE DEVELOPMENT;

T-CELLS;

ANTIGEN; DENDRITIC CELL VACCINE; FERRITIN PROTEIN CAGE NANOPARTICLE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; NANOCARRIER; OT 1 PEPTIDE; OT 2 PEPTIDE; OVALBUMIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SURFACE; CELL SUSPENSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; DRUG DELIVERY SYSTEM; ENDOSOME; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HELPER CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHAGOCYTOSIS; SPLEEN CELL; TH1 CELL; TH2 CELL; ZETA POTENTIAL;

MUS;

ANTIGEN DELIVERY; DENDRITIC CELLS; FERRITIN; PROTEIN CAGE; VACCINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FERRITINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NANOPARTICLES; OVALBUMIN; PEPTIDE FRAGMENTS; TH1 CELLS; TH2 CELLS;

EID: 84896549424     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.11.003     Document Type: Article

References (37)

1. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
2. Steinman R.M. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012, 30:1-22.
3. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
4. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
5. Tacken P.J., de Vries I.J.M., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
6. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001, 1:209-219.
7. Kushnir N., Streatfield S.J., Yusibov V. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31:58-83.
8. Roldao A., Mellado M.C.M., Castilho L.R., Carrondo M.J.T., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9:1149-1176.
9. Elamanchili P., Lutsiak C.M.E., Hamdy S., Diwan M., Samuel J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007, 30:378-395.
10. Manayani D.J., Thomas D., Dryden K.A., Reddy V., Siladi M.E., Marlett J.M., et al. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. Plos Pathog 2007, 3:1422-1431.
11. Peacey M., Wilson S., Baird M.A., Ward V.K. Versatile RHDV virus-like particles: Incorporation of antigens by genetic modification and chemical conjugation. Biotechnol Bioeng 2007, 98:968-977.
12. Richert L.E., Servid A.E., Harmsen A.L., Rynda-Apple A., Han S., Wiley J.A., et al. A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 2012, 30:3653-3665.
13. Savard C., Guerin A., Drouin K., Bolduc M., Laliberte-Gagne M.E., Dumas M.C., et al. Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles. Plos One 2011, 6.
14. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118:6836-6844.
15. Waeckerle-Men Y., Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005, 57:475-482.
16. Kanekiyo M., Wei C.J., Yassine H.M., McTamney P.M., Boyington J.C., Whittle J.R., et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499:102-106.
17. Patterson D.P., Rynda-Apple A., Harmsen A.L., Harmsen A.G., Douglas T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 2013, 7:3036-3044.
18. Uchida M., Kang S., Reichhardt C., Harlen K., Douglas T. The ferritin superfamily: Supramolecular templates for materials synthesis. BBA - Gen Subjects 1800, 2010:834-845.
19. Uchida M., Klem M.T., Allen M., Suci P., Flenniken M., Gillitzer E., et al. Biological containers: Protein cages as multifunctional nanoplatforms. Adv Mater 2007, 19:1025-1042.
20. Kang H.J., Kang Y.J., Lee Y.-M., Shin H.-H., Chung S.J., Kang S. Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform. Biomaterials 2012, 33:5423-5430.
21. Kang Y.J., Park D.C., Shin H.-H., Park J., Kang S. Incorporation of Thrombin Cleavage Peptide into a Protein Cage for Constructing a Protease-Responsive Multifunctional Delivery Nanoplatform. Biomacromolecules 2012, 13:4057-4064.
22. Klem M.T., Young M., Douglas T. Biomimetic synthesis of photoactive alpha-Fe2O3 templated by the hyperthermophilic ferritin from Pyrococus furiosus. J Mater Chem 2010, 20:65-67.
23. Parker M.J., Allen M.A., Ramsay B., Klem M.T., Young M., Douglas T. Expanding the temperature range of biomimetic synthesis using a ferritin from the hyperthermophile Pyrococcus furiosus. Chem Mater 2008, 20:1541-1547.
24. Kang Y.J., Uchida M., Shin H.H., Douglas T., Kang S. Biomimetic FePt nanoparticle synthesis within Pyrococcus furiosus ferritins and their layer-by-layer formation. Soft Matter 2011, 7:11078-11081.
25. Clarke S.R., Barnden M., Kurts C., Carbone F.R., Miller J.F., Heath W.R. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 2000, 78:110-117.
26. Robertson J.M., Jensen P.E., Evavold B.D. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol 2000, 164:4706-4712.
27. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., Rammensee H.G. Exact Prediction of a Natural T-Cell Epitope. Eur J Immunol 1991, 21:2891-2894.
28. Shimonkevitz R., Colon S., Kappler J.W., Marrack P., Grey H.M. Antigen Recognition by H-2-Restriced T-Cells. 2. A Tryptic Ovalbumin Peptide that Substitutes for Processed Antigen. J immunol 1984, 133:2067-2074.
29. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S.I., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
30. Kang S., Oltrogge L.M., Broomell C.C., Liepold L.O., Prevelige P.E., Young M., et al. Controlled assembly of bifunctional chimeric protein cages and composition analysis using noncovalent mass spectrometry. J Am Chem Soc 2008, 130:16527-16529.
31. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
32. Miksa M., Komura H., Wu R., Shah K.G., Wang P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J Immunol Methods 2009, 342:71-77.
33. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243:147-154.
34. Foulds K.E., Zenewicz L.A., Shedlock D.J., Jiang J., Troy A.E., Shen H. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 2002, 168:1528-1532.
35. Oehen S., Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998, 161:5338-5346.
36. Yamane H., Paul W.E. Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev 2013, 252:12-23.
37. Bevan M.J. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004, 4:595-602.